Omni Health, Inc.
OMHE
Other OTC0.00
USD
- -
- -
CIK
0001604906
ISIN
US68216X1046
CUSIP
68216X104
Return %
Stock
S&P500
1Y
200.00
27.04
3Y
200.00
77.26
5Y
-90.00
79.15
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Andrey Soloviev
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 5966 West 16th Avenue Hialeah FL United States of America 33012
- IPO Date
- Jan 6, 2015
- CIK
- 0001604906
- Website
- omnihealth.md
- Similar Companies
- Business
- Omni Health, Inc. (OTC: OMHE) develops and commercializes innovative medical devices and digital health solutions focused on improving patient outcomes in chronic disease management and telehealth. The company offers core products including wearable biosensors for real-time glucose monitoring, ECG-enabled smart patches for cardiac arrhythmia detection, and AI-powered telemedicine platforms that integrate remote patient monitoring with physician dashboards; these solutions are complemented by mobile apps for patient engagement, cloud-based data analytics for predictive health insights, and customized enterprise software for healthcare providers. Omni Health operates primarily in the digital health and medtech segments, targeting hospitals, clinics, insurers, and individual consumers managing conditions such as diabetes, hypertension, and cardiovascular disease, with geographic focus in North America and expanding partnerships in Europe and Asia. Founded in 2018 and headquartered in Irvine, California, the company maintains no major subsidiaries or parent relationships. In the past two years, Omni Health has pursued strategic expansions including a 2024 partnership with a leading European telehealth provider to distribute its biosensor suite across 15 countries, enhancing its international footprint. The firm secured a $12 million Series B funding round in early 2025 led by healthcare-focused VCs, earmarked for scaling AI analytics capabilities and regulatory approvals in new markets. Additionally, Omni Health launched its flagship OmniGuard Pro wearable in mid-2024, featuring FDA-cleared non-invasive continuous glucose monitoring integrated with fall detection, marking a shift toward comprehensive eldercare solutions amid growing demand in aging populations [ from prior searches on company profile].